Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Neural tube defect risk from dolutegravir drops as clinical experience grows

Key clinical point: Expanded patient experience showed a very small increased risk for neural tube defects after dolutegravir treatment at the time of conception.

Major finding: Mothers treated with dolutegravir when they conceived had a 0.19% incidence of neonates born with a neural tube defect.

Study details: Tsepamo, a prospective observational study that’s included 156,846 women infected with HIV who have delivered neonates at any of 18 sites in Botswana during 2014-2020.

Disclosures: The study had no commercial funding. Dr. Zash has been a researcher in studies funded by CytoDyn, Fulcrum, and Gilead. Dr. Gandhi had no commercial disclosures.

Source: Zash R. AIDS 2020.